Abstract Library

#3040 Palliative CT Brachytherapy in Hepatic Metastatic NET

Introduction: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jann H

Authors: Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G,

Keywords: brachytherapy, afterloading, hepatic metastases, local tumor ablation, local tumor control,

#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,

#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues

Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jimenez Fonseca P

Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,

Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,